GlassScriptPhysician profile
Andres Efrain Splenser
NPI 1609910835
$922,619.11
in general payments reported to CMS, 2019-2025
45 companies · $153K in 2025
The $153K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184K · 2020: $116K · 2021: $136K · 2022: $123K · 2023: $91K · 2024: $119K · 2025: $153K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $343K · Travel and Lodging: $9,621 · Food and Beverage: $9,385 · Consulting Fee: $1,660 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $342,663.12 |
| Travel and Lodging | $9,621.41 |
| Food and Beverage | $9,385.32 |
| Consulting Fee | $1,660.00 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $517,476.99 | 2019-2025 | Mounjaro, Jardiance, Baqsimi |
| Novo Nordisk INC | $325,504.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $26,684.61 | 2019-2021 | |
| Madrigal Pharmaceuticals | $22,173.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Sanofi-Aventis U.S. LLC | $21,558.49 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,200.00 | 2020 | |
| Ascensia Diabetes Care US INC. | $822.47 | 2023-2025 | |
| Abbott Laboratories | $584.83 | 2019-2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $454.83 | 2020-2025 | Unithroid |
| Abbvie INC. | $347.75 | 2020-2025 | Synthroid |
| Dexcom, INC. | $300.60 | 2019-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $244.35 | 2024-2025 | Korlym |
| Beta Bionics, INC. | $237.80 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amgen INC. | $224.07 | 2019-2025 | Tepezza |
| Mannkind Corporation | $223.07 | 2019-2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $215.46 | 2019-2025 | Tymlos |
| Ibsa Pharma INC. | $212.74 | 2019-2024 | Tirosint, Licart, Flector |
| Tandem Diabetes Care, INC. | $187.40 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.53 | 2021-2024 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $165.55 | 2020-2022 | |
| Valeritas, INC. | $139.46 | 2019 | |
| Ascendis Pharma Endocrinology INC | $136.29 | 2024-2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $131.24 | 2021-2023 | Gvoke Hypopen |
| Zealand Pharma US, INC. | $130.91 | 2020-2022 | |
| Becton, Dickinson and Company | $117.74 | 2021-2022 | |
| Antares Pharma, INC. | $97.41 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Alexion Pharmaceuticals, INC. | $80.51 | 2022-2025 | Strensiq |
| Vivus LLC | $74.35 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $72.76 | 2023-2025 | Contrave, Nexletol |
| Acella Pharmaceuticals, LLC | $69.00 | 2024-2025 | NP Thyroid 60 |
| Sequel Med Tech, LLC | $66.22 | 2025 | Twiist |
| Cequr Corporation | $59.79 | 2025 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.88 | 2022-2023 | Cycloset |
| Astellas Pharma US INC | $56.23 | 2023-2024 | Veozah |
| Avvisto Therapeutics, LLC | $55.70 | 2025 | Cycloset |
| Amphastar Pharmaceuticals, INC. | $43.14 | 2025 | |
| Insulet Corporation | $40.35 | 2019-2020 | |
| Shire North American Group INC | $36.50 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $34.96 | 2024 | Crysvita |
| Embecta Corp. | $31.24 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Kyowa Kirin, INC. | $28.61 | 2024 | Crysvita |
| Recordati_rare_diseases_inc. | $26.22 | 2025 | Isturisa |
| Medtronic Minimed, INC. | $18.90 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.80 | 2020 | |
| Clarus Therapeutics INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andres Splenser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.